The Pivotal Role of Immune Functional Assays in Deciphering Immune Function Alterations

1 Marion Debombourg^{1, 2}, Guy Oriol¹, Caroline Dupre¹, Chloé Albert-Vega¹, Fabienne Venet^{2,4},

2 Thomas Rimmelé^{3,5}, REALISM study group, Anne Conrad^{2,6,7}, Florence Ader^{2,6,8}, Vincent

- 3 Alcazer^{2,7}, VaccHemInf study group, Karen Brengel-Pesce¹, Aurore Fleurie¹, Sophie Trouillet-
- 4 Assant^{1, 2}, William Mouton^{1, 2,*}
- ¹ Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Lyon Sud 6 Hospital, Oullins-Pierre-Bénite, 69310, France.
- ² International Centre for Research in Infectiology (CIRI), INSERM U1111, CNRS UMR5308, ENS
- 8 Lyon, Claude Bernard Lyon 1 University, Lyon, 69008, France.
- ³ EA 7426 Pathophysiology of Injury \Box Induced Immunosuppression, PI3, Claude Bernard Lyon 1
10 University \Box bioMérieux \Box Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437 Lyon, France.
- University□bioMérieux□Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437 Lyon, France.
- ⁴ Immunology Laboratory, Hôpital Edouard Herriot, Hospices Civils de Lyon, 69437 Lyon, France.
- ⁵ Anesthesia and Critical Care Medicine Department, Hôpital Edouard Herriot, Hospices Civils de
- 13 Lyon, 69437 Lyon, France.
- ⁶ Infectious and Tropical Diseases Department, Hospices Civils de Lyon, Croix-Rousse Hospital,
- 15 Lyon, 69004, France.
- ⁷ Clinical hematology department, Hospices Civils de Lyon, Lyon Sud Hospital, Oullins-Pierre-17 Bénite, 69310, France.
- *⁸* 18 Claude Bernard Lyon I University, Villeurbanne, 69100, France.
- 19

20 *** Correspondence:**

- 21 William Mouton
- 22 william.mouton@chu-lyon.fr
- 23 **Keywords: Immune Dysfunction, Immune Functional Assay, Immune Monitoring Tool,**
- 24 **Transcriptomic Analysis, Method Comparison**
- 25

26 **1 Abstract**

27 Recently, immune function assessment has gained prominence in clinical settings. Immune 28 functional assays (IFAs), involving in vitro stimulation, offer a relevant approach to complement 29 traditional immunomonitoring methods which, while widely used, do not fully capture functional 30 immune capabilities. Despite growing interest in IFAs, their added value remains unclear.

31 To address this gap, our study aimed to determine if insights from IFAs could be replicated with 32 unstimulated immunoprofiling. Using the same analytical pipeline, we compared transcriptomic 33 profiles (Nanostring®) between stimulated (TruCulture®) and unstimulated (PaxGene™) samples 34 from i) patients with an overstimulated immune system 3-4 days post-sepsis onset, and ii) patients 35 undergoing immune reconstitution 6-months post-allogeneic hematopoietic stem cell transplantation 36 (allo-HSCT).

- 37 In sepsis, post-stimulation transcriptomic profiles revealed immune clusters linked to disease severity 38 and outcomes, surpassing traditional markers like mHLA-DR, while baseline analyses failed to 39 generate clinically relevant stratification. Similarly, allo-HSCT patients' post-stimulation data 40 revealed immune heterogeneity and treatment-related alterations not detected using baseline 41 transcriptomic or cellular profiles alone.
- 42 Our findings emphasize the value of IFAs in uncovering functional immune alterations that 43 unstimulated assessments may miss, which could offer deeper insights into immune dysfunction. 44 This study supports IFAs as complementary tools to current clinical practices, enhancing patient
- 45 management with a functional view of immune system dynamics.

46 **2 Introduction**

47 Over the past decade, the assessment of immune function has become a relevant approach for the 48 evaluation of host immune capacities (1–3) and immune reconstitution quality (4,5), as well as 49 disease monitoring (1,6,7) across various research domains and clinical contexts. In this regard, 50 Immune Functional Assays (IFA) have emerged as essential tools (1,8), composed by an *in vitro* 51 stimulation step followed by an analysis of the immune response induced by the stimulation, using a 52 varying degree of analytical complexity. These analyses can range from single cytokine secretion 53 measurement, such as interferon-gamma (9), to more intricate phenotyping techniques, such as 54 multiplex OMIC approaches (10). The employment of IFA, and more particularly TruCulture[®] tubes 55 (Myriad RBM, Austin, USA) combined with Nanostring[®] technology to quantify mRNA gene 56 expression level, allowed us to obtain valuable insights into two distinct immunocompromised 57 populations. In the setting of sepsis, transcriptomic data post-staphylococcal enterotoxin B (SEB) 58 stimulation in TruCulture[®] tubes enabled us to stratify a sepsis population according to severity and 59 proved to be more effective than measurements of mHLA-DR, a marker classically used for immune 60 monitoring (11). In the case of allogenic hematopoietic stem cell transplantation (allo-HSCT), gene 61 expression observed post-SEB and post-lipopolysaccharide (LPS) stimulation allowed to identify 62 immune functional alterations associated with ongoing immunosuppressive treatment at 6 months 63 post-transplantation, which could not be revealed solely through cell count analyses, even though 64 they are considered as reference markers for immune reconstitution (4).

65 Other studies have also highlighted the advantages of employing IFA over traditionally used 66 immunomonitoring tools, such as peripheral white blood cell count or immune cell phenotyping 67 conducted without any *in vitro* stimulation step (12–14). But to date, and to our knowledge, no study 68 has addressed the question of whether a stimulation step is necessary for obtaining information that 69 could enhance the detection of functional immune alterations. Furthermore, direct comparisons 70 between stimulated and unstimulated samples using analytical pipelines differing only on the *in vitro* 71 stimulation step have not been performed, thereby hindering a clear demonstration of the added value 72 of IFA.

73 In this study, we aimed to address this gap by conducting two independent assessments of the added 74 value of *in* vitro stimulation compared to baseline transcriptomic profiles for revealing immune 75 function alterations, in the previously mentioned clinical settings: sepsis progression and immune 76 reconstitution following allo-HSCT.

77 **3 Material & Methods**

78 **3.1 Study population**

79 *Sepsis cohort -* Patients with sepsis were included in the REALISM study (NCT02638779), a 80 prospective longitudinal, single-center observational study, conducted in the anesthesiology and 81 intensive care department of the Edouard Herriot hospital between December 2015 and June 2018 82 (*Hospices Civils de Lyon*, HCL, Lyon, France). Blood sampling was performed 3 to 4 days after 83 septic shock onset. The study protocol was approved by the regional ethics committee (*Comité de* 84 *Protection des Personnes Sud-Est II*, number 2015–42-2).

85 *Allo-HSCT cohort -* Allo-HSCT recipients were included in the prospective, single-center cohort 86 study "VaccHemInf" (NCT03659773) between May 2018 and August 2020 at a median time of 6 87 months post-transplantation at the hematology department of the Lyon university hospital (HCL,

- 88 France). The study protocol was approved by the regional ethics committee (*Comité de Protection*
- 89 *des Personnes Sud-Est V*, Grenoble, France, number 69HCL17_0769).
- 90 For each study, blood samples from 10 healthy volunteers (HVs) were concomitantly obtained from
- 91 the national blood service (*Etablissement Français du Sang*), following the regulatory authorizations
- 92 for the handling and conservation of these samples from the regional ethics committee (*Comité de*
- 93 *Protection des Personnes Sud-Est II*) and the French ministry of research (*Ministère de*
- ⁹⁴*lEnseignement supérieur, de la Recherche et de lInnovation*, DC-2008–64).
- 95 Written informed consent was obtained from each healthy donor and from the patients or their 96 relatives upon inclusion in these studies.

97 **3.2 Sample collection**

98 For each study, at the time of sampling, heparinized-whole blood was collected and incubated in 99 TruCulture[®] tubes (Myriad Rbm, Austin, TX, USA) pre-filled with either LPS or SEB, as previously

- 100 described (4,11). Unstimulated whole blood samples were also collected in PaxGene[™] Blood RNA
- 101 tubes (PreAnalytiX/QIAGEN Inc., Valencia CA, USA) and stored at -80°C.

102 **3.3 Isolation of RNA from PaxGene whole-blood**

103 Total RNA was extracted from whole-blood samples using the PaxGene™ Blood RNA Kit 104 (PreAnalytiX/QIAGEN Inc., Valencia CA, USA). After thawing, blood RNA tubes were centrifuged 105 at 3,000g for 10 min at room temperature (RT). The supernatant was decanted, followed by the 106 addition of 4 ml RNase-free water and redissolving of the pellet. Next, the tube was centrifuged again 107 at 3,000 g for 10 min at RT, and the supernatant was discarded. The pellet was resuspended in 350 µl 108 of buffer BR1 and transferred to a microcentrifuge tube. Next, 300 µl of buffer BR2 and 40 µl of 109 proteinase K were added, mixed, and incubated for 10 min at 55°C using a shaker-incubator at 450 110 rpm. This lysate was transferred to a PaxGene shredder (Qiagen, Valencia, CA) spin column and 111 centrifuged at 20,000 g for 3 min at RT. The supernatant of the flow-through fraction was transferred 112 to a fresh microcentrifuge tube, and 350 µl of 100% ethanol was added and mixed. Then 700 µl of 113 this sample was transferred to a PaxGene RNA spin column and centrifuged at 10,000g for 1 min at 114 RT. The flow-through was discarded, and this step was repeated with the remaining sample from the 115 previous step.

116 Next, 350 µl of buffer BR3 was added onto the RNA spin column, which was centrifuged at 10,000g 117 for 1 min at RT. The flow-through was discarded, and 10 µL of DNase 1 was mixed with 70 µl of 118 buffer RDD in a separate tube. This was pipetted onto the spin column membrane and incubated at 119 20–30°C for 15 min. Then 350 µl of buffer BR3 was added onto the RNA spin column, which was 120 centrifuged at 10,000 g for 1 min at RT. The flow-through was then discarded. Next, 500 µl of buffer 121 BR4 was added onto the RNA spin column, which was centrifuged at 10,000 g for 1 min at RT. The flow-through was discarded, and 500 ul of buffer BR4 was added again onto the RNA spin column flow-through was discarded, and 500 μ l of buffer BR4 was added again onto the RNA spin column 123 and centrifuged at 10,000 g for 3 min at RT. The flow-through was discarded. The RNA spin column 124 was transferred to a 1.5-ml microcentrifuge tube, and 40 µl of buffer BR5 was pipetted onto the 125 column to elute the membrane-bound RNA. The column was then centrifuged at 10,000 g for 1 min 126 at RT. This step was repeated with the same 40-µl buffer BR5, and the eluate was incubated at 65° C 127 for 5 min, then chilled on ice. RNA concentration was estimated using the Nanodrop One 128 spectrophotometer (Thermo Scientific, Swedesboro, NJ) according to the manufacturer's instruction.

129 **3.4 Gene expression analysis**

130 Gene expression was evaluated through a 89- (11) and 144-gene panel (4) using the NanoString[®] 131 technology for the sepsis and allo-HSCT study, respectively. Briefly, 300 ng of RNA were 132 hybridized to the probes at 67 °C for 18 h using a thermocycler (Biometra, Tprofesssional TRIO, 133 Analytik Jena AG, Jena, Germany). After removal of excessive probes, samples were loaded into the 134 nCounter Prep Station (NanoString[®] Technologies, Seattle, WA, USA) for purification and 135 immobilization onto the internal surface of a sample cartridge for 2–3 h. The sample cartridge was 136 then transferred and imaged on the nCounter Digital Analyzer (NanoString[®] Technologies) where 137 color codes were counted and tabulated for each panel of genes. Data treatment and normalization 138 were performed on nSolver[®] analysis software (version 4.0, NanoString[®] Technology) using internal 139 controls and 3 housekeeping genes (detailed in **Table S1 and S2**). Of note, for both cohorts, analyses 140 were conducted using genes with expressions exceeding the background noise threshold in more than 141 75% of individuals, as previously described (4,11).

142 **3.5 Statistical Analysis**

143 Normality testing was performed using the Shapiro-Wilk normality test. The distribution of 144 quantitative data was expressed as mean (range) or median (interquartile range, [IQR]) where 145 appropriate. Cluster analyses were performed using the PAM method with correlation and average 146 distance, as previously described by Albert-Vega et *al.* (11). The alluvial plot was obtained via 147 http://www.bioinformatics.com.cn, a free online platform for data analysis and visualization. 148 Principal component analysis (PCA) was carried out using Partek Genomics Suite software (version 149 7.0; Partek Inc., St. Louis, MO), and Euclidean distances were calculated as previously described by 150 Mouton et *al*. (4). Differences in Euclidean distances between groups were calculated using a non-151 parametric unpaired Wilcoxon test with Benjamini correction. Differences in standard deviations 152 (SD) were calculated using paired Pitman-Morgan test. Statistical analyses were conducted using 153 GraphPad Prism software (version 8; GraphPad software, La Jolla, CA, USA) and R (version R.2.2). 154 *P* values and adjusted *P* values (*P* adj) < 0.05 were considered significant.

155 **4 Results**

156 **4.1 Immune function assessment appears as an essential tool to obtain clinically relevant** 157 **clustering in the context of sepsis**

158 Overall, 28 out of the 30 patients with sepsis as well as 10 HVs initially included in the Albert-Vega 159 et *al.* study were analyzed herein, as 2 unstimulated samples had not been collected. Among these 160 patients, 7 developed a hospital-acquired infection (HAI) during ICU stay, and 3 had died at day 28 161 **(Table S3)**. Following the data control and normalization steps described above, 81 out of 86 genes 162 initially analyzed were kept for analyses through PaxGene™ tubes. To evaluate the added value of 163 the stimulation in identifying immune functional alterations in a sepsis population, statistical analyses 164 and clustering must be conducted using an equal number of patients and genes, whose expression 165 was measured post-stimulation or from PaxGene™ tubes without stimulation. To that end, we first 166 aimed to validate that the conclusions derived from the restricted post-stimulation dataset were 167 consistent with those obtained from the complete dataset published in the Albert-Vega et *al.* study.

168 We thus conducted again the multivariate clustering analysis from gene expression levels post-SEB 169 stimulation using 81 genes, 28 patients with sepsis, and 10 HVs. The analysis found 3 clusters with 170 the same composition as previously described by Albert-Vega et *al.* (**Figure 1 left, Table S4**). The 171 first cluster (n=11) grouped together all the HVs and one patient with sepsis, constituting the 172 healthier cluster, gathering immunocompetent individuals. The second cluster (n=13) included all 173 non-survivors, hence designated as the severe cluster. It was characterized by a diminished immune

174 responsiveness upon *in vitro* SEB stimulation and a specific modulation of genes previously 175 described to be associated with mortality, such as MDC1 and IFIT44L. The third cluster (n=14) 176 included 86% (6/7) of the patients with sepsis who developed a HAI, forming the intermediate 177 cluster. As demonstrated by Albert-Vega et *al.*, these patients exhibited, among other, an 178 upregulation of the HLA family and interferon-related genes, suggesting a potential for immune
179 recovery, implying that patients identified in this cluster may benefit from immunostimulatory 179 recovery, implying that patients identified in this cluster may benefit from immunostimulatory 180 therapy.

181 Having confirmed the consistency of the conclusions that can be drawn from the restricted dataset, 182 we conducted the same analyses on PaxGene™ tubes (**Figure S1.A**). Using the dataset obtained from 183 PaxGeneTM tubes, we identified an equivalent of the healthier cluster comprising all HVs, consistent 184 with observations from the post-stimulation gene dataset. However, in the absence of stimulation, 185 this healthier cluster included 4 of 9 patients with sepsis who had been classified within the severe 186 cluster identified post-SEB stimulation, including patients who exhibited an evident and profound 187 alteration of immune function post-stimulation **(Figure 1 right)**. This discrepancy demonstrates the 188 loss of ability to distinguish immunocompetent individuals among a sepsis population based on gene 189 expression analysis from unstimulated whole blood.

190 Altogether, these results highlight a notable discrepancy in patient stratification according to immune

191 alteration profiles when determined with or without *in vitro* stimulation, and suggest that, during the 192 course of sepsis, immune function assessment can reveal distinct immune profiles that are coherent

193 with clinical characteristics.

194 **4.2 Immune function assessment remains necessary in the context of allo-HSCT to uncover** 195 **immune function alterations**

196 We then evaluated the added value of the stimulation to reveal immune functional alterations in 197 another clinical context, e.g. during the immune reconstitution after allo-HSCT. For this study, 59 of 198 the 60 allo-HSCT recipients and 5 of the 10 HVs initially included were analyzed, as one patient 199 sample did not pass quality control, and no PaxGene™ tubes were available for 5 HVs. Regarding 200 the hematological- and transplant-related characteristics of allo-HSCT recipients included at a 201 median [IQR] of 6.5 [5.8-8.3] months after transplantation, 52.5% had been transplanted due to acute myeloid leukemia, 35.6% had active graft-versus-host disease (GvHD) at inclusion, and 32.2% were 202 myeloid leukemia, 35.6% had active graft-versus-host disease (GvHD) at inclusion, and 32.2% were 203 undergoing immunosuppressive treatment at inclusion **(Table S5).**

- 204 Following the data control and normalization steps, 121 out of 138 and 134 genes initially analyzed 205 post-SEB and -LPS stimulation, respectively, were kept for analyses through PaxGene™ tubes. As 206 for the sepsis study, we first aimed to confirm whether the same conclusions obtained from the entire 207 post-stimulation transcriptomic dataset used in the Mouton et *al.* study could be replicated using the 208 new restricted dataset.
- 209 We thus conducted again the PCA from gene expression levels post-stimulation with either LPS or 210 SEB using 121 genes, 59 allo-HSCT recipients, and 5 HVs. Similarly, post-stimulation gene
211 expression analysis revealed a strong homogeneity among HVs, while allo-HSCT recipients expression analysis revealed a strong homogeneity among HVs, while allo-HSCT recipients 212 represented a more heterogeneous population (**Figure S2**). For quantitative purposes, we once again 213 calculated, using the PCA projection from the restricted dataset, the Euclidean distance of each allo-214 HSCT recipient to the centroid of the HV population, which serves as a reference value for a 215 functional immune response. We hypothesized that a greater distance corresponds to a more impaired 216 immune response and assessed the association between these distances and clinical data. Thus, using 217 this restricted post-stimulation dataset, we were able to confirm an increase in Euclidean distance

218 associated with an ongoing immunosuppressive treatment (median [IQR] 9.71 [4.91-12.6] versus 219 13.77 [11.34-18.43] *P* adj < 0.047, **Table S6**) (4).

220 We then proceeded to conduct the same analyses on PaxGene™ tubes **(Figure S1.B)**. Whether 221 obtained post-stimulation or under unstimulated conditions, the immune profiles projected onto the 222 first 2 principal components of the PCA revealed similar overall variability, explaining 36.6% and 223 36.7% of the overall variance, respectively (**Figure 2.A**). Nevertheless, as illustrated in the PCA 224 overlay, the immune functional heterogeneity of allo-HSCT recipients, captured using gene 225 expression analysis through unstimulated whole blood, was less pronounced. This was supported by 226 two indicators, the inertia of the point cloud formed by the allo-HSCT immune profiles and the SD of 227 the Euclidean distance **(Figure 2.B)**, which were both highly reduced in the unstimulated condition 228 compared to the stimulated one (inertia: 39.4 *vs.* 87.5 and SD: 3.814 *vs.* 6.977, p-value <0.001). In 229 addition, neither ongoing immunosuppressive treatment (**Figure 2.C**) nor any other parameter (**Table** 230 **S7**) could account for the significant increase in the Euclidean distance using the gene expression 231 dataset obtained without whole blood stimulation, in contrast to that obtained post stimulation. It 232 appears that in the context of allo-HSCT, immune function assessment through IFA uncovers a 233 treatment-dependent immune response, which could help improve the monitoring of post-234 transplantation immune reconstitution by complementing the classical markers currently used.

235 **5 Discussion**

236 In this study, we aim to evaluate the added value of IFA in capturing altered immune function 237 compared to unstimulated assays in two distinct clinical contexts. To do so, we compared 238 transcriptomic data obtained after a non-specific whole-blood stimulation in TruCulture® with those 239 acquired using PaxGene samples, employing the same analytical pipeline.

240 In the first context of sepsis immune monitoring, several basal-state biomarkers, i.e., without 241 stimulation step, are routinely used in clinical practice, such as mHLA-DR, CD4+/CD8+ ratio, and 242 circulating IL-10 (15). Indeed, persistent low mHLA-DR expression (16–18), decrease in 243 CD4⁺/CD8⁺ ratio (19–22) as well as an increase circulation in IL-10 (23) have been reported to 244 predict mortality in septic shock. Several studies have already employed IFA to assess functional 245 immunity in this context; as Antonakos et *al*. who demonstrated that TNF- α production post-LPS stimulation on day 3 post-sepsis onset could discriminate patients with sepsis from healthy control 246 stimulation on day 3 post-sepsis onset could discriminate patients with sepsis from healthy control 247 subjects (24), or Mazer et *al.* who used IFN-γ and TNF-α ELISpot assays post-anti-CD3/anti-CD28 antibodies and LPS stimulation, respectively, to depict early, profound and sustained suppression of 249 functional immunity in deceased patients (25). Despite the interest in IFA for assessing immune 250 function, no study has yet clearly assessed the added value of stimulation compared to basal-state 251 biomarkers in depicting immune alterations. Therefore, using the same analytical pipeline employed 252 by Albert-Vega et *al.* (11), which demonstrated relevant stratification based on immune functional 253 profiles during the course of sepsis, we evaluated whether the dataset obtained from unstimulated 254 PaxGene samples collected from the same patients at the same visit could reveal similar results. We 255 observed that the unstimulated dataset did not yield clinically relevant clusters, underscoring the 256 value of stimulation in revealing distinct immune profiles during sepsis.

257 Moreover, our results align with the previous observation made by Albert-Vega et *al.*, showing that 258 patients' stratification according to post-SEB stimulation transcriptomic profiles was more effective 259 than using the commonly employed mHLA-DR marker to underline the heterogeneity in sepsis. This

260 reinforces the relevance of IFA employment in this setting, as also suggested by Wang et *al.* (6).

261 In the second context of allo-HSCT, immune cell counts such as $TCD4^+$ cell count and $CD4^+$ / $CD8^+$ 262 ratio are classically quantified to monitor immune reconstitution post-transplant (26,27). However, 263 despite their widespread clinical use, these approaches provide no information regarding the 264 qualitative characteristics of this immune reconstitution (14,28). In this regard, IFA have 265 demonstrated complementary value to these classically used methods. Gjaerde et *al.* conducted 266 proteomic analysis following whole-blood stimulation in TruCulture®, revealing heterogeneity in 267 cytokine production among patients and identifying a cluster with reduced responses, suggesting 268 possible functional immune deficiency (5). Similarly, Mouton et *al.* used non-specific TruCulture® 269 stimulation coupled with a transcriptomic approach to capture a broad range of immune profiles, 270 identifying altered immune functional profiles associated with ongoing immunosuppressive treatment 271 (4). As for the sepsis context, we aimed to distinctly evaluate the added-value of IFA compared to 272 basal-state biomarkers in deciphering immune alterations. To do so, using the same analytical 273 pipeline as Mouton et *al.*, we analyzed unstimulated PaxGene sample collected from the same 274 patients at the same visit. In comparison with the results obtained post *in vitro* stimulation, the use of 275 unstimulated dataset failed to detect any functional alterations, resulting in homogeneous 276 transcriptomic immune profiles among patients. These profiles were not associated with any clinical 277 event or characteristic, especially with the use of immunosuppressive treatments, contrasting with the 278 findings observed post-stimulation. Once again, these results were in line with conclusion made by 279 Mouton et *al.*, which underlined that a clustering approach post-stimulation using transcriptomic data 280 is more effective than solely analyzing cell counts in revealing the heterogeneity of immune profiles 281 during post-transplant reconstitution. This supports the relevance of IFA, as also suggested by Naik 282 et *al.* (14).

283 However, this study has limitations that need to be addressed. Studies with larger sample sizes will 284 be essential to fully evaluate the clinical utility of IFAs and their potential benefits for patient care. 285 Here, we used previously established bioinformatics pipelines specifically designed for post-286 stimulation data to enable a precise comparison; however, we acknowledge that alternative methods 287 may be more suitable for unstimulated datasets. Finally, studies incorporating longitudinal follow-288 ups of immunocompromised patients at various stages of their conditions would be of interest.

289 Overall, the present analyses showed that the conclusions obtained through a clustering-based 290 stratification of post-stimulation data, in two different clinical contexts could not be replicated using 291 unstimulated samples. We reinforce the interest of IFA as complementary tool to traditional 292 immunomonitoring methods, as already well demonstrated for specific immunity in infectious 293 contexts, such as SARS-CoV-2 (29) or *Mycobacterium tuberculosis* (30). The design of the present 294 study highlighted, for the first time, the added value of the stimulation step in identifying functional 295 immune alterations. This observation could pave the way for, or at least encourage, the broader 296 implementation of IFA as a complementary tool in immunomonitoring.

297

298 **6 Reference**

- 299 1. Müller S, Kröger C, Schultze JL, Aschenbrenner AC. Whole blood stimulation as a tool for 300 studying the human immune system. *Eur J Immunol* (2023) doi: 10.1002/eji.202350519
- 301 2. Urrutia A, Duffy D, Rouilly V, Posseme C, Djebali R, Illanes G, Libri V, Albaud B, Gentien D, 302 Piasecka B, et al. Standardized Whole-Blood Transcriptional Profiling Enables the

- 303 Deconvolution of Complex Induced Immune Responses. *Cell Reports* (2016) 16:2777–2791. 304 doi: 10.1016/j.celrep.2016.08.011
- 305 3. Barateau V, Peyrot L, Saade C, Pozzetto B, Brengel-Pesce K, Elsensohn M-H, Allatif O, 306 Guibert N, Compagnon C, Mariano N, et al. Prior SARS-CoV-2 infection enhances and 307 reshapes spike protein–specific memory induced by vaccination. *Science Translational* 308 *Medicine* (2023) 15: doi: 10.1126/scitranslmed.ade0550
- 309 4. Mouton W, Conrad A, Alcazer V, Boccard M, Bodinier M, Oriol G, Subtil F, Labussière-Wallet 310 H, Ducastelle-Lepretre S, Barraco F, et al. Distinct Immune Reconstitution Profiles Captured by 311 Immune Functional Assays at 6 Months Post Allogeneic Hematopoietic Stem Cell 312 Transplantation. *Transplantation and Cellular Therapy* (2023) 29: doi: 313 10.1016/j.jtct.2022.10.025
- 314 5. Gjærde LK, Brooks PT, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Nielsen SD, 315 Ostrowski SR, Sengeløv H. Functional immune reconstitution early after allogeneic 316 haematopoietic cell transplantation: A comparison of pre- and post-transplantation cytokine 317 responses in stimulated whole blood. *Scandinavian Journal of Immunology* (2021) 94: doi: 318 10.1111/sji.13042
- 319 6. Wang Y, Gloss B, Tang B, Dervish S, Santner-Nanan B, Whitehead C, Masters K, Skarratt K, 320 Teoh S, Schibeci S, et al. Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic 321 Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups 322 With Differential Responses to Immunostimulant Drugs. *Frontiers in Immunology* (2021) 12: 323 https://www.frontiersin.org/articles/10.3389/fimmu.2021.634127 [Accessed January 30, 2024]
- 324 7. Svanberg R, MacPherson C, Zucco A, Agius R, Faitova T, Andersen MA, da Cunha-Bang C, 325 Gjærde LK, Møller MEE, Brooks PT, et al. Early stimulated immune responses predict clinical 326 disease severity in hospitalized COVID-19 patients. *Commun Med* (2022) 2:1–15. doi: 327 10.1038/s43856-022-00178-5
- 328 8. Albert-Vega C, Tawfik DM, Trouillet-Assant S, Vachot L, Mallet F, Textoris J. Immune 329 Functional Assays, From Custom to Standardized Tests for Precision Medicine. *Front Immunol* 330 (2018) 9:2367. doi: 10.3389/fimmu.2018.02367
- 331 9. Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of 332 tuberculosis infection, differentiating from active tuberculosis, and decision making for 333 initiating treatment or preventive therapy of tuberculosis infection. *International Journal of* 334 *Infectious Diseases* (2022) 124:S12–S19. doi: 10.1016/j.ijid.2022.02.047
- 335 10. Saint-André V, Charbit B, Biton A, Rouilly V, Possémé C, Bertrand A, Rotival M, Bergstedt J, 336 Patin E, Albert ML, et al. Smoking changes adaptive immunity with persistent effects. *Nature* 337 (2024) 626:827–835. doi: 10.1038/s41586-023-06968-8
- 338 11. Albert Vega C, Oriol G, Bartolo F, Lopez J, Pachot A, Rimmelé T, Venet F, Leray V, Monneret 339 G, Delwarde B, et al. Deciphering heterogeneity of septic shock patients using immune 340 functional assays: a proof of concept study. *Sci Rep* (2020) 10: doi: 10.1038/s41598-020-73014- 341 2

- 342 12. Haem Rahimi M, Venet F, Lukaszewicz A-C, Peronnet E, Cerrato E, Rimmelé T, Monneret G. 343 Interferon-Gamma-Release assay and absolute CD8 lymphocyte count for acquired 344 immunosuppression monitoring in critically ill patients. *Cytokine* (2024) 174: doi: 345 10.1016/j.cyto.2023.156474
- 346 13. Van Den Brink MRM, Velardi E, Perales M-A. Immune reconstitution following stem cell 347 transplantation. *Hematology* (2015) 2015:215–219. doi: 10.1182/asheducation-2015.1.215
- 348 14. Naik S, Vasileiou S, Aguayo-Hiraldo P, Mukhi S, Sasa G, Martinez C, Krance RA, Gottschalk 349 S, Leen A. Toward Functional Immune Monitoring in Allogeneic Stem Cell Transplant 350 Recipients. *Biology of Blood and Marrow Transplantation* (2020) 26:911–919. doi: 351 10.1016/j.bbmt.2020.01.005
- 352 15. Yao R-Q, Ren C, Zheng L-Y, Xia Z-F, Yao Y-M. Advances in Immune Monitoring Approaches 353 for Sepsis-Induced Immunosuppression. *Front Immunol* (2022) 13: doi: 354 10.3389/fimmu.2022.891024
- 355 16. Monneret G, Lepape A, Voirin N, Bohé J, Venet F, Debard A-L, Thizy H, Bienvenu J, 356 Gueyffier F, Vanhems P. Persisting low monocyte human leukocyte antigen-DR expression 357 predicts mortality in septic shock. *Intensive Care Med* (2006) 32:1175–1183. doi: 358 10.1007/s00134-006-0204-8
- 359 17. Zorio V, Venet F, Delwarde B, Floccard B, Marcotte G, Textoris J, Monneret G, Rimmelé T. 360 Assessment of sepsis-induced immunosuppression at ICU discharge and 6 months after ICU 361 discharge. *Annals of Intensive Care* (2017) 7:80. doi: 10.1186/s13613-017-0304-3
- 362 18. Yang H, Yu Y, Chai J, Hu S, Sheng Z, Yao Y. Low HLA-DR expression on CD14+ monocytes 363 of burn victims with sepsis, and the effect of carbachol *in vitro*. *Burns* (2008) 34:1158–1162. 364 doi: 10.1016/j.burns.2008.01.026
- 365 19. Drewry AM, Samra N, Skrupky LP, Fuller BM, Compton SM, Hotchkiss RS. Persistent 366 Lymphopenia After Diagnosis of Sepsis Predicts Mortality. *Shock* (2014) 42:383. doi: 367 10.1097/SHK.0000000000000234
- 368 20. Menges T, Engel J, Welters I, Wagner R-M, Little S, Ruwoldt R, Wollbrueck M, Hempelmann 369 G. Changes in blood lymphocyte populations after multiple trauma: Association with 370 posttraumatic complications. *Critical Care Medicine* (1999) 27:733.
- 371 21. McDunn JE, Turnbull IR, Polpitiya AD, Tong A, MacMillan SK, Osborne DF, Hotchkiss RS, 372 Colonna M, Cobb JP. Splenic CD4+ T cells have a distinct transcriptional response six hours 373 after the onset of sepsis. *J Am Coll Surg* (2006) 203:365–375. doi: 374 10.1016/j.jamcollsurg.2006.05.304
- 375 22. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC, Osborne DF, 376 Freeman BD, Cobb JP, Buchman TG, et al. Sepsis-Induced Apoptosis Causes Progressive 377 Profound Depletion of B and CD4+ T Lymphocytes in Humans1. *The Journal of Immunology* 378 (2001) 166:6952–6963. doi: 10.4049/jimmunol.166.11.6952

- 379 23. Pachot A, Monneret G, Voirin N, Leissner P, Venet F, Bohé J, Payen D, Bienvenu J, Mougin B, 380 Lepape A. Longitudinal study of cytokine and immune transcription factor mRNA expression in 381 septic shock. *Clinical Immunology* (2005) 114:61–69. doi: 10.1016/j.clim.2004.08.015
- 382 24. Antonakos N, Tsaganos T, Oberle V, Tsangaris I, Lada M, Pistiki A, Machairas N, Souli M, 383 Bauer M, Giamarellos-Bourboulis EJ. Decreased cytokine production by mononuclear cells 384 after severe gram-negative infections: early clinical signs and association with final outcome. 385 *Critical Care* (2017) 21:48. doi: 10.1186/s13054-017-1625-1
- 386 25. Mazer MB, C. Caldwell C, Hanson J, Mannion D, Turnbull IR, Drewry A, Osborne D, Walton 387 A, Blood T, Moldawer LL, et al. A Whole Blood Enzyme-Linked Immunospot Assay for 388 Functional Immune Endotyping of Septic Patients. *The Journal of Immunology* (2021) 206:23– 389 36. doi: 10.4049/jimmunol.2001088
- 390 26. Stein DS, Korvick JA, Vermund SH. CD4+ Lymphocyte Cell Enumeration for Prediction of 391 Clinical Course of Human Immunodeficiency Virus Disease: A Review. *The Journal of* 392 *Infectious Diseases* (1992) 165:352–363. doi: 10.1093/infdis/165.2.352
- 393 27. Margolick JB, Gange SJ, Detels R, O'Gorman MRG, Rinaldo CRJ, Lai S. Impact of Inversion 394 of the CD4/CD8 Ratio on the Natural History of HIV-1 Infection. *JAIDS Journal of Acquired* 395 *Immune Deficiency Syndromes* (2006) 42:620. doi: 10.1097/01.qai.0000223028.55080.9d
- 396 28. Kowalski R, Post D, Schneider MC, Britz J, Thomas J, Deierhoi M, Lobashevsky A, Redfield 397 R, Schweitzer E, Heredia A, et al. Immune cell function testing: an adjunct to therapeutic drug 398 monitoring in transplant patient management. *Clinical Transplantation* (2003) 17:77–88. doi: 399 10.1034/j.1399-0012.2003.00013.x
- 400 29. Mouton W, Oriol G, Compagnon C, Saade C, Saker K, Franc P, Mokdad B, Fleurie A, Lacoux 401 X, Daniel S, et al. Combining SARS-CoV-2 interferon-gamma release assay with humoral 402 response assessment to define immune memory profiles. *Eur J Immunol* (2024) doi: 403 10.1002/eji.202451035
- 404 30. Ortiz-Brizuela E, Apriani L, Mukherjee T, Lachapelle-Chisholm S, Miedy M, Lan Z, 405 Korobitsyn A, Ismail N, Menzies D. Assessing the Diagnostic Performance of New Commercial 406 Interferon-γ Release Assays for Mycobacterium tuberculosis Infection: A Systematic Review
407 and Meta-Analysis. *Clin Infect Dis* (2023) 76:1989–1999. doi: 10.1093/cid/ciad030 407 and Meta-Analysis. *Clin Infect Dis* (2023) 76:1989–1999. doi: 10.1093/cid/ciad030
- 408

409 **7 Author Contributions**

410 All authors were involved in the analysis and interpretation of data, as well as drafting the manuscript 411 or revising it critically for important intellectual content. MD, STA and WM made substantial 412 contributions to the conception and design of the study and designed the experiments. MD and WM 413 performed the experiments. MD, GO, CD, and WM performed the data analyses. MD, WM and STA 414 drafted the manuscript. All authors read and approved the final manuscript. WM and STA take 415 responsibility for the integrity of the data analysis.

416 **8 Conflict of Interest**

417 MD, GO, KBP and AF are employed by the in-vitro diagnostic company bioMérieux.

418 **9 Funding**

- 419 *REALISM study* This work was supported by the French National Research Agency through a grant 420 awarded to BIOASTER (Grant number #ANR-10-AIRT-03) and from bioMérieux, Sanofi and GSK.
- 421 *VaccHemInf FIGHT study* This work was supported by an internal grant from the *Hospices Civils* 422 *de Lyon* (Appel d'Offre Jeune Chercheur 2018, to A.C.); the *Région Auvergne-Rhône-Alpes* (Pack 423 Ambition Recherche 2019, to F.A.)
-
- 424 This work was supported by the public grant overseen by the French National Research Agency 425 (C*haires industrielles 2023)* and supported by the *Association Nationale de la Recherche et de la* 426 *Technologie* (ANRT) with a CIFRE fellowship granted to Marion Debombourg.

427 **10 Acknowledgments**

428 The authors thank Jonathan Lopez, Pauline Berlier and Isabelle Mosnier for their technical assistance

- 429 on Nanostring molecular biology; Verena Landel for language editing and critical reading of the
- 430 manuscript.

431

FIGURE 2

